Based on existing FAP vaccines [12] and the FAP inhibitor (Talabostat) used in preliminary clinical trials, treatments targeting FAP, especially those that inhibit its activity, are expected to offer clinical benefits to patients with T2DM-associated HFpEF. Here, FAP is linked to type 2 diabetes mellitus.